The preclinical biology of a new potent and selective progestin: trimegestone

@article{Winneker2003ThePB,
  title={The preclinical biology of a new potent and selective progestin: trimegestone},
  author={R. Winneker and D. Bitr{\'a}n and Zhiming Zhang},
  journal={Steroids},
  year={2003},
  volume={68},
  pages={915-920}
}
Trimegestone (TMG) is a 19-norpregnane progestin being developed, in combination with an estrogen, for the treatment of postmenopausal symptoms. TMG binds to the human progesterone receptor with an affinity greater than medroxyprogesterone acetate (MPA), norethindrone (NET), and levonorgestrel (LNG). In contrast, TMG binds with low affinity to the androgen, glucocorticoid and mineralocorticoid receptor and has no measurable affinity for the estrogen receptor. Compared to other progestins, TMG… Expand
Preclinical and clinical properties of trimegestone: A potent and selective progestin
TLDR
It may be concluded that TMG provides a clinically proven option in hormone therapy for both clinicians and patients. Expand
Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy.
TLDR
The results suggest that these progestins are unlikeley to exert significant effects via the MR at doses used in hormonal therapy, however, considering their relative free concentrations compared to endogenous hormones, the possibility that NET-A may exhibit significant MR antagonist activity, with some possible cardiovascular protective benefits, should not be excluded. Expand
Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget*
Progesterone receptor (PR) agonists have several important applications in women's health, such as in oral contraception and post-menopausal hormone therapy. Currently, all PR agonists usedExpand
Synthetic progestins used in HRT have different glucocorticoid agonist properties
TLDR
Results suggest that the differences in biological activity of the progestins are not merely due to differences in their affinity for the GR but also due to the induction of different conformational changes in the liganded-GR. Expand
The use of newer progestins for contraception.
TLDR
Several new progestins have been designed to minimize side-effects related to androgenic, estrogenic or glucocorticoid receptor (GR) interactions, and Dienogest (DNG) and drospirenone (DRSP) exhibit a partial antiandrogenic action, and DRSP has predominant anti-mineraloc Corticoid properties. Expand
Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies
TLDR
The inability of reduced metabolite of NES (3α, 5α-THNES) to activate GABAAR suggests that the neuroprotective and myelin regenerative effects of NES are mediated via PR binding and not via its interaction with the GABAAR. Expand
A direct comparison of the transcriptional activities of progestins used in contraception and menopausal hormone therapy via the mineralocorticoid receptor.
TLDR
All progestins except MPA, NET-A and NES will likely compete with aldosterone for binding to the MR in vivo at doses used in hormonal therapy to elicit physiologically significant off-target effects. Expand
Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat
TLDR
Sex hormone effects on TFPI in this model and as reported in women may help to shift the coagulation balance to a more prothrombotic state, which could potentially have an improved clinical profile. Expand
New progestagens for contraceptive use.
TLDR
Several new progestins, including dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG) have been synthesized in the last two decades, designed to have no androgenic or estrogenic actions and to be closer to the physiological hormone P. Expand
Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
TLDR
The molecular mechanisms of intracellular actions of old (MPA, norethisterone, levonorgestrel, gestodene) vs. new (drospirenone, dienogest, trimegestone) generation progestins, via steroid receptors are reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
In vitro characterization of trimegestone: a new potent and selective progestin
TLDR
Data from several in vitro assays demonstrate that TMG is a potent progestin with a better receptor selectivity profile than MPA. Expand
The pharmacological profile of a novel norpregnance progestin (trimegestone).
TLDR
Results show trimegestone to have a favorable pharmacological profile with potent progestomimetic activity, and to be not associated with any unwanted pharmacological effects. Expand
Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
TLDR
Initial animal studies of norgestimate combined with estrogen do not show an attenuation of estrogenic effects, and animal models show that for some parameters, including improvement of lipid profiles, progestins can diminish the cardioprotective effect of estrogen. Expand
Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
TLDR
Drospirenone represents a novel type of synthetic progestogen since it combines potent progestogenic characteristics with antimineralocorticoid and antiandrogenic activity and is anticipated to give rise to a number of additional health benefits both for users of oral contraceptives and hormone replacement therapy recipients. Expand
Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone
TLDR
TMG was a more potent antagonist of estrogenic activity in the uterine endometrium than any of the reference progestins tested and therefore may be more effective in protecting theendometrium in hormone replacement therapy. Expand
Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
TLDR
Complying with the classic contraindications of HRT and selecting molecules devoid of estrogenic, androgenic, or glucocorticoid effect should allow a larger use of the progestins without any major drawback. Expand
Anxiolytic Effect of Progesterone is Mediated by the Neurosteroid Allopregnanolone at Brain GABAA Receptors
TLDR
Evidence is provided that the anxiolytic effect of PROG is not associated with an intracellular steroid receptor that initiates genomic‐mediated responses, and is consistent with a nongenomic mechanism whereby PROG is metabolized to allopregnanolone, a neuroactive steroid that potentiates GABAA receptor‐ mediated responses. Expand
Effects of 17β-estradiol and trimegestone alone ,and in combination ,on the bone and uterus of ovariectomized rats
TLDR
Trimegestone is a novel norpregnane progestin being developed, in combination with 17β-estradiol, for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis and did not block the beneficial effects of 17 β-ESTradiol on bone. Expand
Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia
TLDR
It is concluded that trimegestone, when combined with 17β-estradiol, is a more effective progestin than norethisterone in preventing bone loss in adult ovariectomized rats. Expand
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
TLDR
Lower doses of CEE plus MPA relieve vasomotor symptoms and vaginal atrophy as effectively as commonly prescribed doses. Expand
...
1
2
...